Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Consensus Rating of “Moderate Buy” from Analysts

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) has been given an average rating of “Moderate Buy” by the eight ratings firms that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, six have given a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $28.7143.

A number of analysts have commented on the stock. Zacks Research raised shares of Cullinan Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Wednesday. HC Wainwright boosted their price objective on shares of Cullinan Therapeutics from $26.00 to $27.00 and gave the company a “buy” rating in a research report on Thursday, January 8th. Morgan Stanley restated an “overweight” rating and issued a $30.00 price objective on shares of Cullinan Therapeutics in a research note on Thursday, January 8th. BTIG Research lifted their target price on Cullinan Therapeutics from $32.00 to $38.00 and gave the company a “buy” rating in a research report on Monday, November 24th. Finally, Wall Street Zen lowered Cullinan Therapeutics from a “hold” rating to a “sell” rating in a report on Friday.

Cullinan Therapeutics Stock Performance

CGEM stock opened at $12.50 on Friday. The company has a market cap of $738.45 million, a price-to-earnings ratio of -3.78 and a beta of -0.09. The business’s 50-day moving average is $10.71 and its two-hundred day moving average is $8.56. Cullinan Therapeutics has a fifty-two week low of $5.68 and a fifty-two week high of $13.33.

Cullinan Therapeutics (NASDAQ:CGEM) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.77) EPS for the quarter, beating the consensus estimate of ($0.95) by $0.18. Equities analysts predict that Cullinan Therapeutics will post -3.04 earnings per share for the current year.

Insider Transactions at Cullinan Therapeutics

In related news, insider Jacquelyn L. Sumer sold 3,480 shares of the company’s stock in a transaction on Thursday, December 18th. The shares were sold at an average price of $9.67, for a total value of $33,651.60. Following the completion of the transaction, the insider owned 135,432 shares of the company’s stock, valued at approximately $1,309,627.44. This represents a 2.51% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Jeffrey Alan Jones sold 4,632 shares of the firm’s stock in a transaction dated Thursday, December 18th. The shares were sold at an average price of $9.67, for a total value of $44,791.44. Following the sale, the insider directly owned 169,532 shares in the company, valued at approximately $1,639,374.44. This represents a 2.66% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 33,420 shares of company stock valued at $356,082. Company insiders own 7.16% of the company’s stock.

Hedge Funds Weigh In On Cullinan Therapeutics

A number of hedge funds have recently made changes to their positions in the business. Dynamic Technology Lab Private Ltd bought a new stake in Cullinan Therapeutics during the 1st quarter valued at approximately $163,000. Jane Street Group LLC grew its holdings in Cullinan Therapeutics by 145.9% during the 1st quarter. Jane Street Group LLC now owns 34,396 shares of the company’s stock valued at $260,000 after buying an additional 109,413 shares in the last quarter. Acadian Asset Management LLC bought a new stake in shares of Cullinan Therapeutics during the first quarter valued at approximately $618,000. Y Intercept Hong Kong Ltd bought a new stake in shares of Cullinan Therapeutics during the second quarter valued at approximately $84,000. Finally, Corton Capital Inc. lifted its holdings in shares of Cullinan Therapeutics by 28.9% in the second quarter. Corton Capital Inc. now owns 21,712 shares of the company’s stock worth $163,000 after buying an additional 4,870 shares in the last quarter. Institutional investors own 86.31% of the company’s stock.

Trending Headlines about Cullinan Therapeutics

Here are the key news stories impacting Cullinan Therapeutics this week:

• Positive Sentiment: Zacks upgraded Cullinan from “hold” to “strong-buy,” which can attract momentum and retail flows into the shares. Zacks Research Upgrade
• Positive Sentiment: Technical/momentum coverage notes a big jump in the stock’s Relative Strength (RS) rating to 91 — a sign some quant/momentum-focused investors may increase exposure. Stocks to watch: Cullinan Therapeutics sees RS rating jump to 91
• Neutral Sentiment: Coverage pieces outline what could sustain recent price strength (pipeline progress and upcoming clinical data), but they frame these as potential catalysts rather than confirmed drivers — meaning upside depends on execution. Here’s What Could Help Cullinan Therapeutics (CGEM) Maintain Its Recent Price Strength
• Neutral Sentiment: Analyst-comment roundup / industry insight coverage mentions Cullinan among healthcare names discussed by market analysts; useful context but no single analyst note in that article moved the story materially. Analysts Offer Insights on Healthcare Companies: Cullinan Management (CGEM)…
• Negative Sentiment: A sell-side downgrade by Wall Street Zen to a “sell” rating adds downside pressure and may prompt cautious positioning from some investors. Cullinan Therapeutics (NASDAQ:CGEM) Downgraded to Sell Rating by Wall Street Zen
• Negative Sentiment: Insider Jennifer Michaelson sold 4,000 shares (about $49k at the transaction price), a continuation of prior small sales; while not large versus total insider holdings, repeated insider sales can be interpreted negatively by some investors. Cullinan Therapeutics (NASDAQ:CGEM) Insider Sells $49,200.00 in Stock

Cullinan Therapeutics Company Profile

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.